TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Anosmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of Methadone Enantiomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Methadone Enantiomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apolipoprotein B48 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance and clinical outcomes of the ExploR Modular Radial Head
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Lyme Disease Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Level of functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Achievement of analgesia (decrease of at least 1/3 of pain intensity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height Standard Deviation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAb level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in Screening Referrals for Hearing Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Contraceptive prevalence rate (CPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPI coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Demand for Morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of AF/AFL/AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antiviral activity of TMC114
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tricuspid Annular Peak Systolic Excursion (TAPSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulsed wave tissue Doppler right ventricular velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Desensitized to Peanut Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgG antibodies to pneumococcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cystine stone recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptable ablation percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number and function of regular T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicity as assessed by NCI CTC
Endpoint domain: Adverse events/effects
Primary endpoint: Engraftment toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Peak intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of hyaluronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of Substance P (SP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of neurokinin A (NKA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of neurokinin B (NKB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of hemokinin 1 (HK-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of neurokinin 1 receptor (NK1R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of neurokinin 2 receptor (NK2R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean and percent change in ALP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collagen fragment molecular weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate or severe disability - Bayley III neurodevelopmental outcome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coagulation defect (detection of D-Dimer) of the mother
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Coagulation defect (detection of D-Dimer) of the baby
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Experienced Serious Adverse Events (SAE), Adverse Events (AE) Leading to Discontinuation, or Death
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced Selected Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormalities in Selected Hepatic Clinical Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormalities in Selected Thyroid Clinical Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Composite of All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Need for Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for Mechanical Circulatory Support (MCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maternal HAI Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Patient-reported Acute Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Initial Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test-retest reliability of PFDI-20
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Test-retest reliability of PFIQ-7
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Test-retest reliability of PISQ-12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Test-retest reliability of BSS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Graft Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Score of the Severe Respiratory Insufficiency questionnaire (SRI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Score of the Quality of Life Measure for people with slowly progressive and genetic neuromuscular disease questionnaire (QoL-gNMD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absence from work (sickleave)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Secondary hyperalgesia area (cm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance of Vanadis NIPT for screening of T21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in threshold of ECAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CONECCT endoscopic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Multi-Drug Resistant bacteria carriage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood Oxygen Level Dependent (BOLD) Signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of appropriate atrial sensing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of successfully terminated tachyarrhythmia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serious adverse device effect rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Eligible Patients Consented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Consented Participants Who Complete the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Key Components of BBT Delivered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ambulatory arterial stiffness index (AASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Augmentation index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Sleep Latency Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Time to Fall Back Asleep After Awakening
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Retention of acetal crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for adenoidectomy within one year
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in aortic valve calcium score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Confirmed Hepatorenal Syndrome (HRS) Reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: safety and efficacy of IM olanzapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quantitative HBsAg (qHBsAg) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first major cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of IV injections needed to control DME
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Digit Symbol-Coding test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement according to Packer's Heart Failure Clinical Composite Respond
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain MRI characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Total Percentile Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinically Inactive Disease (CID) Off Glucocorticoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crestal ridge width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Noninvasive Hemoglobin Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Quality of Bimanual Hand Measured by Fugl-Meyer Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Timed Performance of Standardized Manual Activities Measured by Hand Assessment Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive functions (Mean z score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients that discontinued (z-)BZD use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sustained Clinical Response (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of patients suffering from PVT or spleno-mesenteric thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Post void residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Outcome of any pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Functional characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echocardiographic characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 13C (carbon dioxide) production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tumor cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of times youth drank alcohol in the past month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of times youth binge drank in the past month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of times youth used hard drugs in the past month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degrees of Sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Cancer Related Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Progression-free Survival at 4 Months
Endpoint domain: Mortality/survival
Primary endpoint: disease course in patients with Mycobacterium chimaera infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Perceived Stress Scale-14 (PSS-14)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Erectile function (EF) domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the plasma-induced transcriptional assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of thyroid nodule volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensitivity of FDG PET/CT imaging to detect myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time To Neutrophil Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With COWS Score ≥ 13
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social Network Measure
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Psychological Adaptation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lower A1C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adipokines levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Current Major Depression Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative testing of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Toxicity Assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Semmes Weinstein Monofilaments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pinch-holding-up-activity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Manual Tactile Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Purdue pegboard test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: The Valpar 8 simulates assembly work assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of GIST tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Brain activity during emotion conflict
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain activity during emotion regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain activity during cognitive control and emotion response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Length of stay (in days)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 30 day readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Difference in size of the retroperitoneal lymph node mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tinnitus Distress Rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immediate changes in spinal kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Serum Concentration (Cmax) of Tocilizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Serum Concentration (Cmin) of Tocilizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Model predicted Area Under the Serum Concentration-Time Curve from Time Zero to End of Dosing (AUCtau) of Tocilizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of gingival epithelial cells infected by EBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Peripheral Absolute Lymphocyte Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in contractility assessed by the end-systolic pressure-volume relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time from documentation of end-of-life care preferences to death
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of Grade 3 or higher adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Premature study treatment discontinuation due to an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who experience virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HCV treatment-lag time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Substrate utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fatigue Assessment Scale (FAS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Amygdala response to fearful expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reward prediction errors and expected value signaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Conflict related signaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fusion grade by CT assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in absolute total weekly alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Synerchia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Kidney Disease Quality Life Short Form 36 Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of treatment-emergent AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Total PSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall PSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: VSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to return to functional life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pulsed wave doppler resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: UE Accelerometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose level well tolerated based on toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of asthma exacerbations requiring treatment
Endpoint domain: Adverse events/effects
Primary endpoint: HCP assessments of product form and fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likely effectiveness of the product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the product
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes